Steris Plc - STE STOCK NEWS

Evoqua Water Technologies (NYSE: AQUA) announced an agreement to acquire the renal business assets of Mar Cor Purification and Cantel Medical, subsidiaries of STERIS Plc (NYSE: STE), for $196.3 million. This acquisition aims to enhance Evoqua's medical water purification solutions and expand its footprint in the healthcare market. The transaction, expected to close in Q2 FY2022, is projected to generate annual revenues of approximately $180 million and adjusted EBITDA of around $27 million prior to synergies.

STERIS reported a 58% increase in second quarter revenue, reaching $1,197 million, compared to $756 million in Q2 fiscal 2021. The adjusted EPS rose to $1.99 from $1.48 year-over-year. The company indicated a strong recovery in procedure volumes, especially in the U.S., and reiterated its fiscal 2022 outlook for 10-11% organic revenue growth and adjusted EPS of $7.60 to $7.85. However, net income fell to $69.8 million, impacted by acquisition-related costs.

STERIS plc (NYSE: STE) announced a quarterly interim dividend of $0.43 per share, payable on December 17, 2021 to shareholders of record by November 23, 2021. The company emphasizes its role as a global provider focused on enhancing patient care through infection prevention. STERIS aims to create a healthier world with its innovative healthcare, life sciences, and dental products. For further details, visit www.steris.com.

STERIS plc (NYSE: STE) will host a conference call on November 3, 2021, at 10:00 a.m. ET to discuss its fiscal 2022 second quarter financial results. A press release detailing these results will be issued after the U.S. market closes on November 2, 2021. Investors can access the call live or via a replay on the STERIS investor relations website or by phone. STERIS provides innovative healthcare and infection prevention products and services, aiming to support patient care globally.

STERIS reported a strong fiscal 2022 Q1 with a 45% revenue increase to $968.4 million, compared to $668.9 million in Q1 of fiscal 2021. Adjusted net income was $159.9 million or $1.76 per diluted share, up from $113.3 million or $1.32 per diluted share year-over-year. The company increased its fiscal 2022 revenue outlook to approximately $4.6 billion and raised its dividend to $0.43 per share. The integration of Cantel Medical is on track, reflecting solid performance across Healthcare and Applied Sterilization Technologies.

STERIS plc (NYSE: STE) announced a conference call to discuss its fiscal 2022 first quarter financial results, scheduled for August 10, 2021, at 10:00 a.m. ET. Details of the financial results will be released after market close on August 9, 2021. Interested parties can participate via phone or online. STERIS aims to enhance healthcare and life science products globally, emphasizing a commitment to creating a safer world.

STERIS plc (NYSE: STE) has successfully completed the acquisition of Cantel Medical, enhancing its offerings in infection prevention across several sectors, including endoscopy and dental. The acquisition is expected to create more value for customers and shareholders, according to CEO Walt Rosebrough. Financial advisors included Guggenheim Securities for STERIS and Centerview Partners for Cantel. This strategic move aims to bolster STERIS's product range and global reach in the healthcare market, aligning with its mission to promote a healthier world.

STERIS plc reported 4Q21 revenue of $873.5 million, a 6% increase year-over-year, contributing to a 3% full-year growth to $3.1 billion. Diluted earnings per share (EPS) for 4Q21 was $1.02, down from $1.43 in 4Q20, while adjusted EPS remained steady at $1.63. For fiscal 2022, STERIS anticipates revenue around $4.5 billion and adjusted EPS between $7.40 - $7.65. The company also declared a dividend of $0.40 per share.

STERIS plc (NYSE: STE) announced the retirement of David B. Lewis from its Board effective July 29, 2021, after serving since 2010. Paul E. Martin, former CIO at Baxter International, has been appointed as a new Board member as of May 5, 2021. The Board will return to nine members post-Annual Meeting. CEO Walt Rosebrough will also not stand for re-election, with COO Dan Carestio expected to be appointed as new CEO. These transitions aim to enhance Board effectiveness and bring in valuable insights from experienced leaders.